Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)
Decreasing Chemotherapy for HER2 Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Sponsor: NIH
Enrolling: Male and Female Patients
IRB Number: AAAT8168
U.S. Govt. ID: NCT04266249
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study is being done to answer the following question: Can participants with HER2-positive breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after 12 weeks of chemotherapy and two HER-targeted therapies eliminate further chemotherapy after surgery? This would be a decrease in the total number of chemotherapy drugs and the amount of chemotherapy typically received to treat this type of cancer. We are doing this study because we want to find out if this approach can enable you to take fewer chemotherapy drugs than the usual approach for your type of breast cancer without compromising your outcome. The usual approach is defined as care most people get for HER2-positive breast cancer. Usual treatment includes additional chemotherapy drugs that might not be necessary, since the HER2-targeted drugs are so effective.
Investigator
Julia McGuinness, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Do you have HER2-positive breast cancer? Yes No
Are you able to make extra visits to the clinic for treatment and assessments? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162